Fox Run Management L.L.C. Purchases Shares of 11,969 Moderna, Inc. $MRNA

Key Points

• Fox Run Management acquired a new stake in Moderna, buying 11,969 shares valued at approximately $339,000 during Q1 2023.
• Research analysts have set a consensus target price of $43.59 for Moderna, with ratings ranging from Strong Buy to Sell.
• Moderna reported a revenue of $142 million for the latest quarter, exceeding estimates of $116.26 million, but experienced a 41.1% decline in revenue compared to the same quarter last year.

Fox Run Management L.L.C. acquired a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,969 shares of the company's stock, valued at approximately $339,000.

Other large investors also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd purchased a new stake in Moderna in the 1st quarter worth about $25,000. Itau Unibanco Holding S.A. boosted its position in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Moderna during the 1st quarter valued at about $30,000. Vega Investment Solutions bought a new stake in shares of Moderna during the 4th quarter valued at about $45,000. Finally, Sentry Investment Management LLC purchased a new position in shares of Moderna during the 1st quarter valued at about $31,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.90 during trading on Friday, hitting $27.12. The company had a trading volume of 9,158,832 shares, compared to its average volume of 8,197,467. The stock has a 50 day simple moving average of $29.18 and a 200 day simple moving average of $29.12. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $84.28. The firm has a market capitalization of $10.55 billion, a P/E ratio of -3.60 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same quarter last year, the company earned ($3.33) earnings per share. The business's revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on MRNA shares. JPMorgan Chase & Co. set a $26.00 price objective on Moderna in a report on Friday, August 1st. Bank of America reduced their target price on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research note on Tuesday, July 22nd. Evercore ISI set a $32.00 price target on Moderna in a research note on Friday, August 1st. William Blair reissued a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Finally, Leerink Partners dropped their target price on Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $42.88.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.